Form 8-K · Current report
Biogen 8-K, filed Oct 28, 2026
- Filed
- CIK
- 0000875045
- Accession no.
- 0000875045-26-000094
Summary
Biogen reported third-quarter 2026 total revenue of $2.8 billion, up 11% year-over-year, with GAAP diluted EPS of $(0.14) and non-GAAP diluted EPS of $2.62, and raised the lower end of its full-year 2026 non-GAAP diluted EPS guidance to $12.20–$13.00 from $12.00–$13.00. CEO Christopher A. Viehbacher said the results show Biogen has returned to growth, citing the first full quarter of contributions from the acquired Apellis products.
Key points
- Growth Portfolio revenue was $1.26 billion in the quarter, up 49% year-over-year and 63% of Core Pharmaceutical revenue.
- GAAP and non-GAAP results included $284 million of acquired IPR&D, upfront and milestone expense, primarily related to the acquisition of RayThera Inc.
- Biogen expects top-line data from the TOPAZ-1 and TOPAZ-2 Phase 3 trials of litifilimab in SLE in the first half of December 2026.
- As of September 30, 2026, Biogen held about $1.3 billion in cash and cash equivalents and about $7.7 billion in total debt.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On October 28, 2026, Biogen Inc. issued a press release announcing its results of operations and financial condition for the third quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933 or…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.